HanAll's IMVT-1402 Cracks Tough RA: New Hope for Refractory Patients
Baca dalam 60 detik
- The trial enrolled 120 patients with moderate-to-severe RA who failed at least two biologics or JAK inhibitors.
- IMVT-1402 achieved ACR20 response in 68% of patients at 12 weeks, versus 22% for placebo.
- Safety profile mirrored prior studies, with no new serious infections or thrombotic events.
The trial enrolled 120 patients with moderate-to-severe RA who failed at least two biologics or JAK inhibitors. IMVT-1402 achieved ACR20 response in 68% of patients at 12 weeks, versus 22% for placebo. Safety profile mirrored prior studies, with no new serious infections or thrombotic events.
Mechanistically, IMVT-1402 accelerates degradation of pathogenic IgG autoantibodies by blocking neonatal Fc receptor (FcRn). This reduces synovial inflammation without broad immunosuppression, a key differentiator from TNF blockers and JAK inhibitors. Analysts project peak sales exceeding $2 billion if Phase 3 data replicate these results.
HanAll plans to advance IMVT-1402 into pivotal trials by Q4 2024, targeting both RA and myasthenia gravis. The dual program leverages overlapping FcRn biology across autoimmune indications. Partnering discussions with Big Pharma are underway, given the drug's potential to become a backbone therapy for refractory patients.
Power Move: IMVT-1402's success reshapes the RA treatment ladder, challenging incumbents like AbbVie's Humira and Pfizer's Xeljanz. HanAll's next move: lock in a global partner to fund Phase 3 and accelerate label expansion into lupus and ITP. First-mover advantage in FcRn targeting could yield a $5 billion franchise by 2030.
This article was edited with AI assistance for readability. Read original here.
